Leerink Partnrs Has Positive Outlook of KYTX Q2 Earnings

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) – Research analysts at Leerink Partnrs increased their Q2 2025 EPS estimates for shares of Kyverna Therapeutics in a research note issued on Tuesday, May 13th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($0.87) for the quarter, up from their previous forecast of ($1.13). The consensus estimate for Kyverna Therapeutics’ current full-year earnings is ($3.29) per share. Leerink Partnrs also issued estimates for Kyverna Therapeutics’ Q3 2025 earnings at ($0.76) EPS, Q4 2025 earnings at ($0.77) EPS, FY2025 earnings at ($3.43) EPS, FY2026 earnings at ($3.18) EPS, FY2027 earnings at ($3.81) EPS, FY2028 earnings at ($3.91) EPS and FY2029 earnings at ($3.16) EPS.

A number of other brokerages have also recently issued reports on KYTX. Morgan Stanley lowered their price objective on Kyverna Therapeutics from $40.00 to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 1st. HC Wainwright decreased their price target on Kyverna Therapeutics from $6.00 to $4.00 and set a “neutral” rating on the stock in a research report on Thursday, April 3rd. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $18.33.

Kyverna Therapeutics Price Performance

KYTX opened at $2.32 on Friday. The company has a market capitalization of $100.27 million, a price-to-earnings ratio of -0.67 and a beta of 2.17. Kyverna Therapeutics has a 1 year low of $1.78 and a 1 year high of $17.06. The firm’s fifty day moving average price is $2.14 and its two-hundred day moving average price is $3.28.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Tuesday, May 13th. The company reported ($1.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.21) by $0.18.

Hedge Funds Weigh In On Kyverna Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC lifted its holdings in Kyverna Therapeutics by 21.5% during the third quarter. Barclays PLC now owns 70,167 shares of the company’s stock valued at $343,000 after purchasing an additional 12,418 shares in the last quarter. Kera Capital Partners Inc. purchased a new position in shares of Kyverna Therapeutics in the fourth quarter worth $1,407,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Kyverna Therapeutics in the 4th quarter valued at about $34,000. Rhumbline Advisers lifted its holdings in shares of Kyverna Therapeutics by 31.1% in the 4th quarter. Rhumbline Advisers now owns 25,920 shares of the company’s stock valued at $97,000 after acquiring an additional 6,153 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Kyverna Therapeutics by 1.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 169,780 shares of the company’s stock valued at $635,000 after acquiring an additional 3,145 shares during the last quarter. Hedge funds and other institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial.